RS58712B1 - Derivati policikličnih amida kao cdk9 inhibitori - Google Patents
Derivati policikličnih amida kao cdk9 inhibitoriInfo
- Publication number
- RS58712B1 RS58712B1 RS20190564A RSP20190564A RS58712B1 RS 58712 B1 RS58712 B1 RS 58712B1 RS 20190564 A RS20190564 A RS 20190564A RS P20190564 A RSP20190564 A RS P20190564A RS 58712 B1 RS58712 B1 RS 58712B1
- Authority
- RS
- Serbia
- Prior art keywords
- amide derivatives
- cdk9 inhibitors
- polycyclic amide
- polycyclic
- cdk9
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 | |
| PCT/EP2016/064899 WO2017001354A1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
| EP16733459.8A EP3313838B1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS58712B1 true RS58712B1 (sr) | 2019-06-28 |
Family
ID=56292699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20190564A RS58712B1 (sr) | 2015-06-29 | 2016-06-27 | Derivati policikličnih amida kao cdk9 inhibitori |
| RS20220005A RS62781B1 (sr) | 2015-06-29 | 2016-06-27 | Policiklični amidni derivati kao inhibitori cdk9 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220005A RS62781B1 (sr) | 2015-06-29 | 2016-06-27 | Policiklični amidni derivati kao inhibitori cdk9 |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US9845331B2 (sr) |
| EP (2) | EP3539961B1 (sr) |
| JP (1) | JP6997627B2 (sr) |
| KR (1) | KR102663113B1 (sr) |
| CN (1) | CN107873028B (sr) |
| AR (1) | AR105179A1 (sr) |
| AU (1) | AU2016286200B2 (sr) |
| BR (1) | BR122019013677B1 (sr) |
| CA (1) | CA2989499C (sr) |
| CL (1) | CL2017003306A1 (sr) |
| CO (1) | CO2017013713A2 (sr) |
| CR (2) | CR20170596A (sr) |
| CY (2) | CY1122111T1 (sr) |
| DK (2) | DK3313838T3 (sr) |
| DO (2) | DOP2017000295A (sr) |
| EA (1) | EA035383B1 (sr) |
| ES (2) | ES2902148T3 (sr) |
| HR (2) | HRP20211970T1 (sr) |
| HU (2) | HUE057343T2 (sr) |
| IL (1) | IL256393B (sr) |
| LT (2) | LT3313838T (sr) |
| ME (1) | ME03404B (sr) |
| MX (1) | MX371034B (sr) |
| NI (1) | NI201700174A (sr) |
| PE (1) | PE20180530A1 (sr) |
| PH (1) | PH12017502334A1 (sr) |
| PL (2) | PL3539961T3 (sr) |
| PT (2) | PT3313838T (sr) |
| RS (2) | RS58712B1 (sr) |
| SI (2) | SI3539961T1 (sr) |
| SV (1) | SV2017005598A (sr) |
| TN (1) | TN2017000486A1 (sr) |
| TR (1) | TR201909286T4 (sr) |
| TW (1) | TWI723028B (sr) |
| WO (1) | WO2017001354A1 (sr) |
| ZA (1) | ZA201800563B (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020005039A2 (pt) | 2017-09-25 | 2020-09-15 | Astrazeneca Ab | combinação de um inibidor de btk e um inibidor de cdk9 para tratar câncer |
| US11319295B2 (en) | 2017-10-09 | 2022-05-03 | Merck Sharp & Dohme Corp. | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN114786673A (zh) * | 2019-09-11 | 2022-07-22 | 普莱鲁德疗法有限公司 | Cdk抑制剂及其作为药物的用途 |
| JP2023505850A (ja) * | 2019-12-09 | 2023-02-13 | 石薬集団中奇制薬技術（石家庄）有限公司 | サイクリン依存性キナーゼ９阻害剤としての化合物及びその用途 |
| US20230219961A1 (en) | 2020-05-12 | 2023-07-13 | Suzhou Alphama Biotechnology Co., Ltd. | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof |
| CN113149996B (zh) * | 2020-05-12 | 2022-12-20 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 |
| JP2023542065A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ |
| CA3188521A1 (en) | 2020-08-07 | 2022-02-10 | Zuozhong PENG | Cdk9 inhibitor and use thereof |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| CN115381824A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| WO2023284775A1 (zh) * | 2021-07-14 | 2023-01-19 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| TW202333679A (zh) * | 2021-12-23 | 2023-09-01 | 比利時魯汶大學 | 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之四氫吡唑并嘧啶及相關類似物 |
| WO2024039210A1 (ko) | 2022-08-17 | 2024-02-22 | 한국화학연구원 | Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| JP5693951B2 (ja) | 2007-04-24 | 2015-04-01 | アストラゼネカ エービー | プロテインキナーゼの阻害剤 |
| US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| US8389521B2 (en) | 2007-04-24 | 2013-03-05 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2008132138A1 (en) * | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| SI2212297T1 (sl) | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | Inhibitorji protein kinaz |
| EP2473502A1 (en) * | 2009-09-04 | 2012-07-11 | Novartis AG | Heteroaryl compounds as kinase inhibitors |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| CA2789189A1 (en) | 2010-03-10 | 2011-09-15 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| EP2668162A1 (en) * | 2011-01-28 | 2013-12-04 | Novartis AG | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| US9314026B2 (en) | 2011-10-06 | 2016-04-19 | Bayer Intellectual Property Gmbh | Heterocyclylpyri(mi)dinylpyrazole |
| US8969375B2 (en) | 2013-03-13 | 2015-03-03 | Abbvie, Inc. | CDK9 kinase inhibitors |
| CN105189481A (zh) * | 2013-03-13 | 2015-12-23 | 艾伯维公司 | 吡啶cdk9激酶抑制剂 |
| UY35419A (es) | 2013-03-14 | 2014-10-31 | Abbvie Inc | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina |
| CA2903538A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Pyrrolopyrimindine cdk9 kinase inhibitors |
-
2016
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en active Application Filing
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active IP Right Grant
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-15 PH PH12017502334A patent/PH12017502334A1/en unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-04-19 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201800563B (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| ME03740B (me) | Jedinjenja indol karboksamida korisna kao inhibitori kinaze | |
| IL266745A (en) | Benzodiazolonium compounds as enac inhibitors | |
| HK1257565A1 (zh) | 作為htra1抑制劑的新型三氟甲基丙酰胺衍生物 | |
| HK1257567A1 (zh) | 作為htra1抑制劑的新型二氟酮酰胺衍生物 | |
| HK1253572A1 (zh) | 作為tnap抑制劑的吡啶並噁嗪酮化合物 | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 |